Biogen’s Tecfidera Launch Unlikely to Be Hampered By Generic Substitution

by Elizabeth Krutoholow

 

Biogen’s Tecfidera is unlikely to face competition from generic dimethyl fumarate, according to physicians interviewed.

The company introduced its oral multiple sclerosis (MS) drug in the U.S. in the second quarter this year. In its recent earnings call, Biogen said the launch is “going very well.”

 

Read More >>>

Bloomberg BRIEF Newsletters